Wemplat 50mg Injection

• Ovarian cancer
• Cervical cancer
• Testicular cancer

Like any other medicine, Wemplat 50mg Injection also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Blood clots in vein
• Fast, irregular or slow heartbeats
• Difficulty in breathing
• Sepsis
• Decrease in bone marrow function
• Decrease in the number of WBC, RBC, Platelets (thrombocytopenia) sodium in blood
• High temperature
• Vomiting

Serious

• Allergic reactions
• Neuropathy
• Kidney problems
• Severe chest pain
• Pain or swelling at the site of injection
• Confusion, slurry speech, paralysis
• Stroke

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Wemplat 50mg Injection is a prescription-based anticancer drug. It is advised to take this injection after consulting your healthcare expert.
• This medicine should be given intravenously by an experienced nurse or doctor. Please do not self-administer.​​
  

• Wemplat 50mg Injection is a prescription based anticancer with Cisplatin as an active ingredient which is platinum-based chemotherapy medication.
• It is an alkylating agent that works by destroying genetic material like DNA or RNA of the cancer cells to prevents the replication of rapidly growing cancer cells. Cisplatin causes the DNA strands to cross-link, that stops the cells from dividing and ultimately leads to their death.
• As it can cause some adverse impact on the body because it affects both healthy & cancerous cells.​​
  

• Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021). Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. Journal of experimental pharmacology, 303-328. https://pubmed.ncbi.nlm.nih.gov/33776489/
• Romani, A. M. (2022). Cisplatin in cancer treatment. Biochemical pharmacology, 206, 115323. https://pubmed.ncbi.nlm.nih.gov/36368406/
• Hill, G. W., Morest, D. K., & Parham, K. (2008). Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otology & Neurotology, 29(7), 1005-1011. https://pubmed.ncbi.nlm.nih.gov/18716567/
• Authier, N., Gillet, J. P., Fialip, J., Eschalier, A., & Coudore, F. (2003). An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Experimental neurology, 182(1), 12-20. https://pubmed.ncbi.nlm.nih.gov/12821373/
• Kartalou, M., & Essigmann, J. M. (2001). Mechanisms of resistance to cisplatin. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 478(1-2), 23-43.
• Prestayko, A. W., D'aoust, J. C., Issell, B. F., & Crooke, S. T. (1979). Cisplatin (cis-diamminedichloroplatinum II). Cancer treatment reviews, 6(1), 17-39.